SS-31 Molecular Structure & Chemical Properties

SS-31, also known as elamipretide, represents a breakthrough in mitochondria-targeted peptide therapeutics, with development spanning over two decades and culminating in FDA approval in September 2025 for Barth syndrome. Originally discovered serendipitously during opioid receptor research at Weill Cornell Medical College, this synthetic tetrapeptide has been extensively studied in over 50 clinical trials and hundreds of preclinical investigations. Unlike conventional antioxidants that diffuse throughout cellular compartments, SS-31’s unique aromatic-cationic structure enables selective targeting of the inner mitochondrial membrane where it binds to cardiolipin, a critical phospholipid essential for mitochondrial structure and bioenergetic function. This targeted mechanism distinguishes SS-31 from other mitochondrial interventions and underlies its therapeutic potential across diverse pathologies involving mitochondrial dysfunction.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide’s structure features alternating aromatic and cationic residues creating an amphipathic character that facilitates membrane penetration. The dimethyltyrosine (Dmt) residue provides antioxidant capacity through its ability to scavenge reactive oxygen species, while the D-arginine confers resistance to enzymatic degradation.

SS-31 Mechanism of Action

SS-31 peptide exerts its biological effects through a multi-faceted mechanism centered on mitochondrial membrane stabilization and optimization of bioenergetic efficiency. Unlike single-target therapeutics, SS-31’s activity involves interaction with both lipid and protein components of the inner mitochondrial membrane, with cardiolipin binding serving as the primary driver of its protective effects.

Primary Cellular Pathways

Cardiolipin Binding – Membrane Stabilization

Research has demonstrated that SS-31 selectively binds to cardiolipin, an anionic phospholipid highly enriched in the inner mitochondrial membrane[1]. This interaction:

• Stabilizes cristae structure and prevents aberrant remodeling during stress
• Maintains optimal geometry for respiratory chain supercomplex assembly
• Protects cardiolipin from peroxidation by reactive oxygen species
• Preserves mitochondrial membrane potential under pathological conditions

Studies using chemical cross-linking with mass spectrometry revealed that SS-31 binds to cardiolipin-enriched membrane domains where respiratory complexes assemble[2]. This localization is driven by electrostatic interactions between the peptide’s cationic residues and cardiolipin’s negative charge.

Mitochondrial Protein Interactions – Bioenergetic Optimization

Beyond lipid interactions, SS-31 directly engages with mitochondrial proteins involved in energy metabolism[3]. Proteomic analyses identified 12 key protein interactors:

• ATP synthase complex components (Complex V)
• Adenine nucleotide translocator (ANT) – improves ADP/ATP exchange efficiency
• Electron transport chain proteins – enhances electron flux and reduces leak
• 2-oxoglutarate metabolism enzymes – modulates Krebs cycle regulation

These protein interactions contribute to improved oxidative phosphorylation efficiency and increased ATP production capacity in energy-depleted mitochondria.

Antioxidant Activity – ROS Scavenging

SS-31 peptide possesses intrinsic antioxidant properties through its dimethyltyrosine residue[4]:

• Scavenges superoxide and hydroxyl radicals
• Reduces peroxidation of membrane lipids and proteins
• Decreases mitochondrial reactive oxygen species production
• Prevents oxidative damage to mitochondrial DNA

Unlike traditional antioxidants, SS-31’s membrane localization enables targeted ROS neutralization at the primary site of oxidant generation within the electron transport chain.

Mitochondrial Dynamics Modulation

Research indicates SS-31 influences mitochondrial morphology and quality control processes[5]:

• Promotes formation of larger, more interconnected mitochondrial networks
• Enhances mitophagy (selective removal of damaged mitochondria)
• Reduces excessive mitochondrial fragmentation under stress
• Improves mitochondrial protein import efficiency

Anti-Apoptotic Signaling

SS-31 demonstrates cytoprotective effects through multiple apoptosis-regulatory pathways[6]:

• Inhibits cytochrome c release from mitochondria
• Reduces BAX protein recruitment to mitochondrial outer membrane
• Prevents mitochondrial permeability transition pore opening
• Maintains mitochondrial calcium handling capacity

SS-31 Research Applications & Key Findings

Mitochondrial Disease Research

Barth Syndrome Studies

Barth syndrome, caused by mutations in the TAZ gene affecting cardiolipin synthesis, represents SS-31’s most clinically advanced application. The TAZPOWER clinical trial demonstrated[7]:

• 45% improvement in knee extensor muscle strength at 48 weeks
• 40% enhancement in cardiac stroke volume
• Significant improvements in 6-minute walk test performance
• Sustained benefits in long-term open-label extension (over 8 years)

FDA accelerated approval was granted in September 2025, making SS-31 (branded as Forzinity) the first approved treatment for Barth syndrome and the first FDA-approved mitochondria-targeted therapeutic.

Primary Mitochondrial Myopathy

Phase 2/3 trials in patients with inherited mitochondrial diseases showed[8]:

• Improved mitochondrial respiratory chain function
• Dose-dependent increases in muscle ATP production
• Enhanced exercise tolerance in some patient subgroups
• Generally well-tolerated with mild injection site reactions

However, primary endpoints were not consistently met across all mitochondrial myopathy subtypes, indicating variable responsiveness based on specific genetic defects.

Cardiovascular Research

Heart Failure and Cardiac Protection

Extensive preclinical and clinical research has examined SS-31 in cardiac pathologies[9,10]:

• Preserved cardiac function following ischemia-reperfusion injury in animal models
• Improved left ventricular ejection fraction in dog models of heart failure
• Enhanced mitochondrial ATP production in failing human heart tissue
• Reduced myocardial infarct size in experimental coronary occlusion

Clinical trials in heart failure with reduced ejection fraction (PROGRESS-HF) showed trends toward improvement but did not achieve primary efficacy endpoints, highlighting challenges in translating preclinical promise to heterogeneous patient populations.

Renal Protection Research

Ischemia-Reperfusion Injury

Studies in renal artery stenosis and acute kidney injury demonstrated[11,12]:

• Attenuated post-procedural hypoxia following renal artery stenting
• Increased renal blood flow three months post-intervention
• Improved glomerular filtration rate in treated patients
• Reduced oxidative stress markers in kidney tissue

Diabetic Nephropathy

Research in diabetic kidney disease models showed[13]:

• Inhibition of mitochondrial fission and dysfunction
• Reduced tubulointerstitial injury and fibrosis
• Improved mitochondrial membrane potential in renal tubular cells
• Decreased proteinuria and preserved kidney architecture

Neurodegenerative Disease Research

Cognitive Function and Neuroprotection

Preclinical studies in neurodegeneration models revealed[14,15]:

• Improved memory performance in lipopolysaccharide-induced cognitive impairment models
• Reduced neuronal apoptosis in traumatic brain injury models
• Enhanced synaptic density and dendritic spine preservation
• Decreased neuroinflammation and oxidative damage in hippocampus

Mouse models of age-related cognitive decline showed restoration of mitochondrial function in brain tissue with corresponding improvements in behavioral testing.

Retinal and Ophthalmic Research

Age-Related Macular Degeneration

Studies in dry AMD and related retinal pathologies demonstrated[16]:

• Improved photoreceptor function in aged mice
• Reversal of age-related visual decline when treatment initiated at 24 months
• Protection against oxidative damage in retinal pigment epithelium
• Enhanced retinal blood flow and reduced drusen formation

Clinical trials (ReCLAIM studies) in intermediate AMD patients showed acceptable safety profiles with exploratory efficacy signals warranting continued investigation.

Skeletal Muscle and Aging Research

Sarcopenia and Exercise Tolerance

Research in aged animal models revealed remarkable effects on muscle function[17,18]:

• Significant increase in gastrocnemius muscle mass in aged mice
• Improved treadmill endurance capacity (increased running time and distance)
• Enhanced mitochondrial ATP production without increasing mitochondrial content
• Reduced muscle fatigue resistance and faster recovery

Eight-week treatment with SS-31 in 26-month-old mice restored mitochondrial function to levels approaching young animals, with corresponding improvements in physical performance.

SS-31 Pharmacokinetics & Metabolism

Absorption & Distribution

SS-31 exhibits favorable pharmacokinetic properties for a peptide therapeutic, with research in multiple species demonstrating[19,20]:

• Rapid tissue uptake following subcutaneous or intravenous administration
• Selective accumulation in mitochondria-rich tissues (heart, kidney, skeletal muscle, liver)
• Crosses blood-brain barrier with measurable brain concentrations
• Independent of mitochondrial membrane potential for cellular uptake

Distribution studies using radiolabeled peptide showed preferential localization to the inner mitochondrial membrane within 15-30 minutes of administration. Peak plasma concentrations occur within 1 hour of subcutaneous injection, with tissue concentrations persisting longer than plasma levels.

Metabolism & Elimination

Pharmacokinetic characterization reveals[21]:

• Plasma half-life of less than 4 hours in humans (approximately 2-3 hours)
• Metabolized primarily through peptidase-mediated degradation
• Resistance to rapid degradation due to D-arginine residue
• Dose-proportional pharmacokinetics across clinical dose ranges

A notable pharmacodynamic observation is the dissociation between short plasma half-life and prolonged biological effects. Improvements in mitochondrial function and clinical outcomes persist for days to weeks after treatment cessation, suggesting either tissue retention, downstream signaling cascade activation, or structural remodeling effects that outlast drug presence.

Excretion Pathways

Elimination characteristics include[22]:

• Renal excretion as primary clearance route
• No evidence of drug accumulation with chronic dosing
• Clearance proportional to renal function
• Minimal hepatic metabolism contribution

Studies in renal impairment models showed altered pharmacokinetics, though the peptide remained well-tolerated even in compromised kidney function, likely due to its mitochondrial protective effects offsetting potential accumulation concerns.

SS-31 Research Protocols & Administration

Dosing in Published Research

Research investigations across species and indications have employed varied SS-31 doses:

Preclinical Studies:

• Mouse models: 3-5 mg/kg/day (most common for chronic studies)
• Rat studies: 1-10 mg/kg (range depending on pathology model)
• Dog models: 0.05 mg/kg/hour (continuous intravenous infusion)
• Non-human primates: 0.05-0.25 mg/kg (pharmacokinetic studies)

Human Clinical Trials:

• Intravenous administration: 0.01-0.25 mg/kg/hour for 1-4 hours
• Subcutaneous injection: 40 mg/day (Barth syndrome studies)
• Safety studies: Up to 4 mg/kg single dose well-tolerated

Important: These are experimental doses used in controlled research studies and cannot be extrapolated to other species or conditions due to significant differences in pharmacokinetics, mitochondrial density, disease pathophysiology, and drug metabolism. Species-specific factors including body surface area, metabolic rate, and tissue distribution profoundly influence both efficacy and safety profiles. Clinical dosing must be determined through formal dose-escalation trials in target populations.

Administration Routes in Research

Multiple delivery methods have been investigated across studies:

• Subcutaneous injection – Primary route in Barth syndrome trials; once-daily administration; good patient acceptance
• Intravenous infusion – Used in acute settings (myocardial infarction, renal artery intervention); allows precise dose titration
• Continuous infusion – Employed in chronic heart failure studies; maintains steady plasma levels
• Bolus injection – Utilized in some animal studies for acute injury models

The subcutaneous route emerged as the preferred clinical administration method due to ease of self-administration, consistent absorption, and suitability for chronic therapy.

Common Model Organisms

SS-31 has been extensively studied across multiple experimental systems:

• Mice (C57BL/6, aged mice, genetic knockout models) – Primary preclinical model; extensive aging and disease studies
• Rats (Sprague-Dawley, Wistar) – Used in cardiac and renal injury models
• Dogs (mongrel dogs, heart failure models) – Cardiac function and chronic disease studies
• Rabbits – Ischemia-reperfusion and cardiovascular research
• Non-human primates – Pharmacokinetic and toxicology studies
• Cell culture (primary cardiomyocytes, neurons, kidney cells, patient-derived cells) – Mechanistic investigations and disease modeling

Human studies have been conducted in healthy volunteers, patients with Barth syndrome, primary mitochondrial myopathy, heart failure, age-related macular degeneration, and renal artery stenosis.

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite over 20 years of research and recent FDA approval for Barth syndrome, SS-31 faces important translational limitations that constrain broader application.

Variable Clinical Trial Outcomes

The most significant challenge has been inconsistent translation of preclinical efficacy to clinical benefit:

• Heart failure trials (PROGRESS-HF) failed to meet primary endpoints despite robust preclinical data
• Primary mitochondrial myopathy studies showed variable responses across genetic subtypes
• Endpoint selection challenges in rare disease populations with heterogeneous phenotypes
• Placebo effects and subjective outcome measures complicated interpretation

These failures highlight the complexity of applying a single therapeutic to diverse mitochondrial diseases with different underlying genetic defects and pathophysiologies.

Mechanistic Understanding Gaps

Fundamental questions about SS-31’s mechanism remain incompletely resolved:

• Relative contribution of cardiolipin binding versus protein interactions to clinical effects
• Why biological effects persist long after drug clearance from plasma
• Which of multiple mechanisms (antioxidant, bioenergetic, structural) is most critical for different diseases
• Optimal biomarkers to predict responders versus non-responders

Long-Term Safety Considerations

Critical safety questions requiring continued investigation:

• Chronic effects beyond 8 years of treatment (longest available human data from Barth syndrome trials)
• Potential impacts on normal mitochondrial turnover and biogenesis
• Effects during pregnancy and development (limited data available)
• Interaction potential with medications affecting mitochondrial function
• Cancer risk considerations (mitochondrial function influences both tumor suppression and progression)

Regulatory & Competitive Sport Status

FDA Position

SS-31 has a complex regulatory history culminating in recent approval[23]:

• Approved for Barth syndrome in patients weighing at least 30 kg (September 2025)
• Granted under accelerated approval pathway based on muscle strength surrogate endpoint
• Continued approval contingent on confirmatory trials demonstrating clinical benefit
• Not approved for other indications including heart failure, mitochondrial myopathy, or age-related conditions
• Received Orphan Drug, Fast Track, Priority Review, and Rare Pediatric Disease designations

For conditions beyond Barth syndrome, SS-31 remains an investigational compound. The FDA has required additional evidence before considering broader indications.

International Status

• European Medicines Agency: Orphan Drug Designation for Barth syndrome; no marketing authorization to date
• Other jurisdictions: Investigational status; no approved indications outside United States

WADA Prohibition

Competitive sport considerations:

• Not explicitly prohibited by World Anti-Doping Agency as of current prohibited list
• Classification as unapproved pharmacological substance in most jurisdictions may create regulatory complexity
• Athletes should verify status with their specific sport governing body
• Potential future consideration under metabolic modulators if performance-enhancing effects demonstrated

Research Classification: SS-31 (elamipretide) is FDA-approved solely for treatment of Barth syndrome in patients weighing at least 30 kg. For all other applications, SS-31 is available only for laboratory research use. It is not intended for human consumption outside approved indications, medical use in unapproved conditions, or veterinary applications. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

References

1. Mitchell, W., Ng, E.A., Tamucci, J.D., Boyd, K.J., Sathappa, M., Coscia, A., Pan, M., Han, X., Eddy, N.A., May, E.R., Szeto, H.H., & Alder, N.N. (2020). The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. Journal of Biological Chemistry, 295(21), 7452-7469. PubMed
   
2. Chavez, J.D., Tang, X., Campbell, M.D., Reyes, G., Kramer, P.A., Stuppard, R., Keller, A., Zhang, H., Rabinovitch, P.S., Marcinek, D.J., & Bruce, J.E. (2020). Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences, 117(26), 15363-15373. PubMed
   
3. Stuppard, R.S., Sapa, A.P., Mamedova, A., Reyes, G., Pham, U., Lee, J., Sweeney, M.G., Campbell, M.D., Sweet, I.R., & Marcinek, D.J. (2023). The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT). GeroScience, 45(5), 3529-3548. PubMed
   
4. Szeto, H.H. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology, 171(8), 2029-2050. PubMed
   
5. Grosser, J.A., Fehrman, R.L., Mohan, R., & Nickells, R.W. (2021). The effects of a mitochondrial targeted peptide (elamipretide/SS31) on BAX recruitment and activation during apoptosis. BMC Research Notes, 14(1), 198. PubMed
   
6. Yang, L., Zhao, K., Calingasan, N.Y., Luo, G., Szeto, H.H., & Beal, M.F. (2009). Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Antioxidants & Redox Signaling, 11(9), 2095-2104. PubMed
   
7. Reid Thompson, W., Hornby, B., Manuel, R., Bradley, E., Laux, J., Carr, J., Vernon, H.J., & on behalf of the TAZ-POWER study group. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine, 23(3), 471-478. PubMed
   
8. Karaa, A., Haas, R., Goldstein, A., Vockley, J., & Cohen, B.H. (2020). A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. Journal of Cachexia, Sarcopenia and Muscle, 11(4), 909-918. PubMed
   
9. Chatfield, K.C., Sparagna, G.C., Chau, S., Phillips, E.K., Ambardekar, A.V., Aftab, M., Mitchell, M.B., Sucharov, C.C., Miyamoto, S.D., & Stauffer, B.L. (2019). Elamipretide improves mitochondrial function in the failing human heart. JACC: Basic to Translational Science, 4(2), 147-157. PubMed
   
10. Sabbah, H.N., Gupta, R.C., Kohli, S., Wang, M., Hachem, S., & Zhang, K. (2016). Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure. Circulation: Heart Failure, 9(2), e002206. PubMed
    
11. Saad, A., Herrmann, S.M.S., Eirin, A., Ferguson, C.M., Glockner, J.F., Bjarnason, H., McKusick, M.A., Misra, S., Lerman, L.O., & Textor, S.C. (2017). Phase 2a clinical trial of mitochondrial protection (elamipretide) during stent revascularization in patients with atherosclerotic renal artery stenosis. Circulation: Cardiovascular Interventions, 10(9), e005487. PubMed
    
12. Sweetwyne, M.T., Pippin, J.W., Eng, D.G., Hudkins, K.L., Chiao, Y.A., Campbell, M.D., Marcinek, D.J., Alpers, C.E., Szeto, H.H., Rabinovitch, P.S., & Shankland, S.J. (2017). The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age. Kidney International, 91(5), 1126-1145. PubMed
    
13. Miyamoto, S., Zhang, G., Hall, D., Oates, P.J., Maity, S., Madesh, M., Han, X., & Sharma, K. (2020). Restoring mitochondrial superoxide levels with elamipretide (MTP-131) protects db/db mice against progression of diabetic kidney disease. Journal of Biological Chemistry, 295(21), 7249-7260. PubMed
    
14. Zhao, K., Luo, G., Giannelli, S., & Szeto, H.H. (2005). Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochemical Pharmacology, 70(12), 1796-1806. PubMed
    
15. Yin, X., Manczak, M., & Reddy, P.H. (2016). Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington’s disease. Human Molecular Genetics, 25(9), 1739-1753. PubMed
    
16. Siegel, M.P., Kruse, S.E., Percival, J.M., Goh, J., White, C.C., Hopkins, H.C., Kavanagh, T.J., Szeto, H.H., Rabinovitch, P.S., & Marcinek, D.J. (2013). Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell, 12(5), 763-771. PubMed
    
17. Campbell, M.D., Duan, J., Samuelson, A.T., Gaffrey, M.J., Merrihew, G.E., Egertson, J.D., Wang, L., Bammler, T.K., Moore, R.J., White, C.C., Kavanagh, T.J., Voss, J.G., Szeto, H.H., Qian, W.J., Rabinovitch, P.S., MacCoss, M.J., & Marcinek, D.J. (2019). Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radical Biology and Medicine, 134, 268-281. PubMed
    
18. Chiao, Y.A., Zhang, H., Sweetwyne, M., Whitson, J., Ting, Y.S., Basisty, N., Pino, L.K., Quarles, E., Nguyen, N.H., Campbell, M.D., Zhang, T., Gaffrey, M.J., Merrihew, G., Jung, Y.S., Wehber, E.D., Poss, K.D., Marcinek, D.J., Qian, W.J., MacCoss, M.J., & Rabinovitch, P.S. (2020). Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice. eLife, 9, e55513. PubMed
    
19. Birk, A.V., Liu, S., Soong, Y., Mills, W., Singh, P., Warren, J.D., Seshan, S.V., Pardee, J.D., & Szeto, H.H. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 24(8), 1250-1261. PubMed
    
20. Birk, A.V., Chao, W.M., Bracken, C., Warren, J.D., & Szeto, H.H. (2014). Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. British Journal of Pharmacology, 171(8), 2017-2028. PubMed
    
21. Karaa, A., Haas, R., Goldstein, A., Vockley, J., Weaver, W.D., & Cohen, B.H. (2018). Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology, 90(14), e1212-e1221. PubMed
    
22. Butler, J., Khan, M.S., Anker, S.D., Fonarow, G.C., Kim, R.J., Nodari, S., O’Connor, C.M., Pieske, B., Pieske-Kraigher, E., Sabbah, H.N., Shah, S.J., Teerlink, J.R., Voors, A.A., Gheorghiade, M., & PROGRESS-HF Investigators. (2020). Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: the PROGRESS-HF phase 2 trial. Journal of Cardiac Failure, 26(5), 429-437. PubMed
    
23. U.S. Food and Drug Administration. (2025). FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. FDA Press Release, September 19, 2025.

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. SS-31 is FDA-approved only for Barth syndrome in patients weighing at least 30 kg. For all other applications, SS-31 is intended for laboratory research use only.